| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.3 | 0.2 |
| Gross profit | 0.1 | 0.1 |
| Profit before tax | -2.0 | -1.8 |
| Net income | -2.0 | -1.8 |
| EPS (diluted, $ a share) | $-0.02 | $-0.02 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +71.7% |
|---|---|
| Gross margin | 18.6% |
Source
Read the filing ↗
10-Q filed with the SEC, NYSE: IGC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
IGC Pharma, Inc.: key numbers
- Share price
- $0.1750Close, Nov 16
- Market cap
- $20.4M
- Shares outstanding
- 116.69MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.